Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma
Our findings provide the first evidence that parthenolide can overcome BRAFi resistance in melanoma, highlighting its potential as a lead compound for the development of Hsp90α inhibitors to manage BRAFi-resistant cutaneous melanoma.
Authors
- Wilson M. S. Tsui (ORCID: https://orcid.org/0000-0001-6710-1576)
- Xiu‐Qiong Fu (ORCID: https://orcid.org/0000-0002-1458-9720)
- Ying Wu (ORCID: https://orcid.org/0000-0001-9196-9586)
- Huanbiao Mo (ORCID: https://orcid.org/0000-0001-7329-8117)
- Jia‐Ying Wu (ORCID: https://orcid.org/0000-0003-0805-1163)
- Amy Sze-Man Li
- Jinjin He (ORCID: https://orcid.org/0000-0002-6532-3295)
- Li Wang (ORCID: https://orcid.org/0000-0002-7004-4725)
- Xiaoqi Wang
- Xiaofei Yu (ORCID: https://orcid.org/0000-0001-8268-903X)
- Ri Han (ORCID: https://orcid.org/0000-0002-9406-3752)
- Guanghua Lu
- Zhi-Ling Yu
- Bin Liu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Hong Kong Baptist University (HK)
- Georgia State University (US)
- Tseung Kwan O Hospital (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Chinese University of Hong Kong, Shenzhen (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1016/j.phymed.2025.157151
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 0.00